As expected of CBP/p300 as critical transcriptional co-activators, RNA polymerase II transcription is the top-ranked pathway among CBP/p300 binding partners that are upregulated in luminal breast tumors versus normal tissues (FC ≥ 1.25, q < 0.05). This evidence concerns the gene EP300 and breast neoplasm.